000			02295 a2200565 4500
005			20250513132834.0
264		0	_c19980210
008			199802s 0 0 eng d
022			_a0888-8809
024	7		_a10.1210/mend.11.13.0041 _2doi
040			_aNLM _beng _cNLM
100	1		_aBand, C J
245	0	0	_aEarly signaling events triggered by peroxovanadium [bpV(phen)] are insulin receptor kinase (IRK)-dependent: specificity of inhibition of IRK-associated protein tyrosine phosphatase(s) by bpV(phen). _h[electronic resource]
260			_bMolecular endocrinology (Baltimore, Md.) _cDec 1997
300			_a1899-910 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAnimals
650	0	4	_aCarcinoma, Hepatocellular
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDrug Synergism
650	0	4	_aEnzyme Activation _xdrug effects
650	0	4	_aHumans
650	0	4	_aInsulin _xpharmacology
650	0	4	_aInsulin Receptor Substrate Proteins
650	0	4	_aIntracellular Signaling Peptides and Proteins
650	0	4	_aLiver Neoplasms
650	0	4	_aOrganometallic Compounds _xpharmacology
650	0	4	_aPhenanthrolines _xpharmacology
650	0	4	_aPhosphatidylinositol 3-Kinases _xdrug effects
650	0	4	_aPhosphoproteins _xdrug effects
650	0	4	_aPhosphorylation _xdrug effects
650	0	4	_aPrecipitin Tests
650	0	4	_aProtein Tyrosine Phosphatase, Non-Receptor Type 11
650	0	4	_aProtein Tyrosine Phosphatase, Non-Receptor Type 6
650	0	4	_aProtein Tyrosine Phosphatases _xantagonists & inhibitors
650	0	4	_aRats
650	0	4	_aReceptor, Insulin _xantagonists & inhibitors
650	0	4	_aRecombinant Fusion Proteins
650	0	4	_aSH2 Domain-Containing Protein Tyrosine Phosphatases
650	0	4	_aSignal Transduction _xdrug effects
650	0	4	_aSubstrate Specificity _xdrug effects
650	0	4	_aTumor Cells, Cultured
650	0	4	_aTyrosine _xmetabolism
650	0	4	_asrc Homology Domains _xdrug effects
700	1		_aPosner, B I
700	1		_aDumas, V
700	1		_aContreres, J O
773	0		_tMolecular endocrinology (Baltimore, Md.) _gvol. 11 _gno. 13 _gp. 1899-910
856	4	0	_uhttps://doi.org/10.1210/mend.11.13.0041 _zAvailable from publisher's website
999			_c9384972 _d9384972